Key Highlights

● Net revenue fell about 9% to roughly 68 million Canadian dollars in the first quarter.

● International medical revenue rose about 17% to roughly 43 million Canadian dollars on German demand.

● Canadian medical revenue fell about 25% after reimbursement rates dropped roughly 30% on April 1.

● Aurora has no debt and about 149 million Canadian dollars in cash and short-term deposits.

Aurora Cannabis (NASDAQ:ACB) has spent the past year reshaping itself into a company focused almost entirely on global medical cannabis. Its latest earnings update covered the first quarter of fiscal 2027 and was released on Wednesday, August 5.

The quarter, which ended June 30, was the first to feel the full effect of a change in Canadian federal reimbursement rates for medical cannabis that took effect on April 1. Revenue declined, adjusted EBITDA fell sharply and free cash flow turned negative. At the same time, the net loss narrowed, German sales grew and the balance sheet remained free of debt.

All amounts are in Canadian dollars.

What did Aurora Cannabis report for its first quarter of fiscal 2027?

According to the company, Aurora generated net revenue of about $67.5 million in the quarter, down about 9% from roughly $74 million in the same quarter a year earlier. The decline came entirely from Canadian medical and consumer sales, since international medical revenue grew.

Adjusted gross margin before fair value adjustments was about 58%, down from about 64%. Adjusted SG&A, the company's measure of overhead costs excluding certain items, edged down to about $35 million from about $36 million. Lower revenue with essentially flat costs explains why adjusted EBITDA dropped to about $3.5 million from nearly $11 million a year earlier.

The reported result was better than the adjusted trend indicates. Net loss from continuing operations narrowed to about $4 million from about $10 million, and adjusted net earnings were about $4 million versus about $7 million. The company attributed its continuing strength to international growth and what it called leading adjusted gross margins, a claim that is relative to peers.

How much did German demand lift Aurora Cannabis' international medical sales?

International medical cannabis revenue rose about 17% to roughly $43 million from about $37 million. The company attributed the increase mainly to higher demand in Germany, which has become the largest European market for medical cannabis supplied through pharmacies.

International medical now makes up roughly two-thirds of total revenue by simple arithmetic on the reported figures. That is a marked shift from earlier years, when Canadian adult-use sales were the core of the business. Aurora has said its strategy is to build a supply network meeting the EU-GMP standard, a pharmaceutical-grade manufacturing certification that European regulators require for imported medical cannabis products.

The company's full-year release in June noted that it expects growth in Germany and Poland in the current fiscal year to partly offset lower Canadian reimbursement. Growth in those markets depends on patient numbers, prescribing behavior and regulatory decisions in each country, so while the first quarter confirmed the trend, it does not guarantee the pace will continue.

Why did Aurora Cannabis' Canadian medical revenue fall so sharply?

Canadian medical cannabis revenue declined about 25% to roughly $21 million from nearly $28 million. The company explained that federal reimbursement changes effective April 1 lowered rates by roughly 30%. The affected program covers eligible veterans, and the rate paid for each gram directly affects what producers collect.

The same change affected Canopy Growth (NASDAQ:CGC), which described its response in its own filings through pricing, product mix and patient retention. For Aurora, the effect was visible immediately because the Canadian medical business is a large, high-margin component of revenue. The medical adjusted gross margin fell to about 61% from about 69%, reflecting the lower reimbursed price.

The company had warned in June that total net revenue for the fiscal year would decline for this reason. The first quarter therefore did not surprise on direction, and the open question is how much patients and prescribers can offset the price cut through volume. The release did not say whether additional rate changes are expected, and it is not described how many patients have shifted products or suppliers since the change took effect. Because reimbursement is set by a federal program rather than by Aurora, the company can influence its own pricing, mix and service levels but not the underlying rate, which leaves a degree of uncertainty that management cannot fully control.

What is Aurora Cannabis doing with its consumer cannabis business?

Consumer cannabis revenue dropped to about $2 million from nearly $8 million as the company winds down that business. Aurora has said it is exiting low-margin Canadian consumer and plant propagation businesses so that it can focus resources on global medical cannabis, which its chief executive has called its most attractive area for growth.

The exit has two effects. It reduces revenue in the near term and removes a volatile, price-sensitive channel from the mix. It also lowers the amount of working capital tied up in inventory and lets management concentrate on higher-margin patient-based sales.

A related portfolio move came earlier in the year, when Aurora divested its 50.1% stake in the Bevo Agtech plant propagation business on February 17. Bevo is now reported as discontinued operations, which is why the continuing results exclude it. Prior-period figures have been recast to reflect those changes.

How does the Safari Flower acquisition fit Aurora Cannabis' supply strategy?

Aurora closed the acquisition of Safari Flower Company in mid-April. The total price was about $26.5 million, including about $15 million in cash and shares valued at roughly $11.5 million. The deal added a cultivation and manufacturing facility of about 59,000 square feet that meets the EU-GMP standard.

In July the company announced that the Ontario facility received a three-year EU-GMP certification. That certification matters because it allows product from the site to be supplied to European markets that require it, adding capacity beyond what Aurora already operates. Management has said it plans growth capital spending of about $3.5 million over three years at the site.

For a company facing lower Canadian reimbursement, additional EU-GMP supply supports the plan of shifting weight toward Europe, Australia and other international medical markets. It also adds acquisition-related integration work, though the first quarter release did not point to meaningful costs from it. Any benefit to revenue would likely appear in later quarters as the certified capacity is brought on line.

What does Aurora Cannabis' balance sheet look like after the quarter?

Aurora reported cash, cash equivalents and short-term deposits of about $149 million at the end of June, with no debt and working capital of about $320 million. At the end of the prior fiscal year the corresponding cash figure was about $165 million, so liquidity declined by roughly $15 million over the quarter.

Part of that decrease reflects the cash paid for the Safari acquisition and part reflects negative free cash flow of about $6 million in the quarter. A year earlier Aurora had generated positive free cash flow of nearly $7 million. The swing is consistent with lower adjusted EBITDA and with spending tied to the new facility.

A debt-free balance sheet is a point of difference among Canadian cannabis producers, several of which carry convertible notes or term loans. It limits interest costs and reduces exposure to refinancing, though it does not insulate the company from the operating challenge posed by lower reimbursement. Management has not announced a share retirement program or dividend in the sources reviewed.

What guidance did Aurora Cannabis give for the fiscal year?

The company said its full-year guidance for fiscal 2027 is unchanged from June. That guidance calls for total net revenue to decline, adjusted gross margin before fair value adjustments in the mid-to-high 50% range, adjusted SG&A broadly in line with the prior year and adjusted EBITDA lower than the roughly $54 million reported for fiscal 2026.

For the second quarter, management said it expects both revenue and adjusted EBITDA to be sequentially higher than the first. Chief Executive Miguel Martin tied that expectation to rising global patient demand for medical cannabis. Sequential improvement is a concrete marker against which the next report can be measured.

Guidance of this kind is an expectation, not a result. It depends on German demand continuing, on Canadian volume stabilizing after the rate change and on the company controlling costs, and any of those could move differently from management's plan.

How did Aurora Cannabis end the prior fiscal year?

In its June release, Aurora reported record annual global medical cannabis net revenue of about $289 million, up about 18%, and record adjusted EBITDA of nearly $54 million, up about 32%. Free cash flow for the year was negative about $14 million, compared with positive about $11 million the year before.

The fourth quarter showed the early signs of pressure. Total net revenue rose about 10% to nearly $85 million, but adjusted gross margin fell to about 60% from 65%, adjusted EBITDA dropped to about $9 million from about $14 million, and the net loss from continuing operations widened to about $28 million.

Against that backdrop the first quarter is another step down on EBITDA, and the guidance explicitly points to a lower full-year figure. The record results were achieved before the reimbursement cut, which is why the company has framed the current year as one of adjustment while it expands internationally.

How does Aurora Cannabis compare with Canopy Growth, Tilray and SNDL?

Within the Canadian group, Aurora is the most focused on medical cannabis and the most international in its revenue. Canopy Growth also has a large Canadian medical business and recently reported revenue growth, but it carries debt and a loss at the adjusted EBITDA level. Tilray Brands (NASDAQ:TLRY) has built a diversified platform around beverages and distribution, and SNDL (NASDAQ:SNDL) leans on retail.

Aurora's margins stand out: an adjusted gross margin near 60% is well above what the other three report on a consolidated basis. The trade-off is concentration. Its results depend heavily on a small set of regulated markets, and regulatory decisions in Canada and Germany can move revenue quickly, as the April reimbursement change showed.

Differences in strategy also show in capital structure. Aurora has cash and no debt, and a relatively small acquisition has been its main use of cash this year. That conservatism gives it room to absorb a slow quarter, but it also means there is no cushion of revenue from lower-margin businesses if medical demand softens.

What should market participants watch next at Aurora Cannabis?

The next report, covering the second fiscal quarter, is the first test of management's expectation for sequential gains in revenue and adjusted EBITDA. A date has not been confirmed, but the company has typically reported in early November.

Other items include German patient growth and pricing, the stabilization of Canadian medical volume, the contribution of the Safari site, and cash usage relative to the roughly $149 million on hand. Further portfolio changes, such as additional exits from non-core businesses, are also possible.

The earnings trend has softened, and management has said the second quarter should be better.